Hackensack 385 Prospect Avenue Suite 101 Hackensack, NJ, 07601

Marlton 127 Church Road Suite 203 Marlton, NJ 08053





Long Branch 422 Morris Avenue Suite 7 Long branch, NJ 07740

Somerset 81 Veronica Avenue Suite 202 Somerset NJ 08873

## Ublituximab-xiiy (Briumvi)

Provider \_\_\_\_\_

Provider Order Form	Date:
PATIENT INFORMATION	
Name:	DOB: SEX: M   F
ICD-10 code (required):	ICD-10 description:
□NKDA Allergies:	Weight lbs/kg:
REFERRAL STATUS	
□New Referral □Referral Renewal □Medication/Order Change □Benefits Verification Only □Discontinuation Order	
PHYSICIAN INFORMATION	
Referral Coordinator Name:	Referral Coordinator Email:
Ordering Provider:	Provider NPI:
Referring Practice Name:	Phone: Fax:
Practice Address:	City: State: Zip Code:
NURSING  ☐ Hepatitis B status & date (list results here & attach clinicals)  ☐ Provide nursing care per ThrIVewell Procedures, including reaction management and post-procedure observation  Based on the manufacturer PI, most payors require a quantitative serum immunoglobulin screening prior to Briumvi induction.  ☐ Ihave attached results from a recent quantitative serum immunoglobulin test (list results here & attach clinicals):  ☐ linstruct ThrIVewell to draw quantitative serum immunoglobulin prior to first induction infusion (if required by payor).  LABORATORY ORDERS  ☐ CBC ☐ at each dose ☐ every ☐ CRP ☐ at each dose ☐ every ☐ CRP ☐ at each dose ☐ every ☐ Other: ☐ Dose: ☐ Route ☐ Frequency: ☐ PRE-MEDICATION ORDERS  ☐ a cetaminophen (Tylenol) ☐ 500mg / ☐ 650mg / ☐ 1000mg PO ☐ methylprednisolone (Solu-Medrol) ☐ 40mg / ☐ 125mg IV ☐ diphenhydramine (Benadryl) ☐ 25mg / ☐ 50mg ☐ PO / IV  ADDITIONAL PRE-MEDICATION ORDERS ☐ cetirizine (Zyrtec) 10mg PO ☐ loratadine (Claritin) 10mg PO ☐ Other: ☐ Dose: ☐ Route: ☐ Frequency: ☐ Route: ☐ Frequency: ☐ Route: ☐ Frequency: ☐ Prequency: ☐ Route: ☐ Frequency: ☐ Prequency: ☐ Prequency: ☐ Procedure Attach clinicals (Claritin) 10mg PO ☐ Other: ☐ Dose: ☐ Route: ☐ Frequency: ☐ Prequency: ☐ Prequency: ☐ Procedure Attach clinicals (Procedure Attach clinicals): ☐ Procedure Attach clinicals (	THERAPY ADMINISTRATION  □ Ublituximab-xiiy (Briumvi) intravenous infusion □ Induction: □ Dose: 150mg in 250ml 0.9% NS over four hours followed by 450mg in 250ml 0.9% NS over one hour two weeks later. After induction, continue with the maintenance dosing and schedule below.  □ Maintenance: □ Dose: 450mg in 250ml 0.9%NS over one hour 24 weeks after the first infusion and every 24 weeks thereafter.  □ Flush with 0.9% NS at the completion of infusion □ Patient required to stay for 60 minute observation post infusion of first two infusions. If no infusion reaction or hypersensitivity has been observed, patient is not required to stay for subsequent infusions.  □ Refills: □ Zero / □ for 12 months / □ (if not indicated order will expire one year from date signed)  SPECIAL INSTRUCTIONS
ORDERING PROVIDER Signature X	Date

Phone\_\_\_\_\_

Fax \_